ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 171.90% from the stock’s previous close.
ImmunoPrecise Antibodies Price Performance
Shares of IPA opened at $3.31 on Friday. The company has a market cap of $82.52 million, a P/E ratio of -3.85 and a beta of 0.60. The stock has a fifty day moving average price of $4.33 and a 200 day moving average price of $4.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.10 and a quick ratio of 2.89. ImmunoPrecise Antibodies has a 12 month low of $3.17 and a 12 month high of $6.50.
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) last issued its quarterly earnings data on Thursday, December 15th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09). ImmunoPrecise Antibodies had a negative return on equity of 39.89% and a negative net margin of 126.00%. The company had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.91 million. On average, research analysts forecast that ImmunoPrecise Antibodies will post -0.71 earnings per share for the current year.
Institutional Inflows and Outflows
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes.
- Get a free copy of the StockNews.com research report on ImmunoPrecise Antibodies (IPA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.